Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 30 2021 - 8:46AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2021
Commission
File Number: 001- 39167
Molecular
Data Inc.
11/F,
Building 15, 2177 Shenkun Road
Minhang
District, Shanghai 201106
People’s
Republic of China
(Address of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Explanatory
Note:
On
November 29, 2021, the NASDAQ Stock Market (“NASDAQ”) granted Molecular Data Inc. (the “Company”)
an additional 180 calendar days, or until May 23, 2022, to regain compliance with the $1.00 per share minimum required for continued
listing on The NASDAQ Capital Market pursuant to NASDAQ Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Rule”).
As
previously reported, on May 25, 2021, the Company received a notification letter (the “Notice”) from NASDAQ
advising the Company that for 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common
stock had closed below the $1.00 per share minimum required for continued listing on The NASDAQ Capital Market pursuant to the Minimum
Bid Price Rule. The Company was provided 180 calendar days, or until November 22, 2021, to regain compliance with the Minimum Bid Price
Rule. The Company was unable to regain compliance with the Minimum Bid Price Rule by November 22, 2021. The NASDAQ determination to grant
the second compliance period was based on the Company’s meeting the continued listing requirement for market value of publicly
held shares and other applicable requirements for initial listing on The NASDAQ Capital Market, with the exception of the bid price requirement,
and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse
stock split, if necessary.
To
regain compliance, the bid price of the Company’s common stock must close at or above $1.00 per share for a minimum of ten consecutive
business days at any time during the second 180-day compliance period. The Company intends to monitor the closing bid price of its common
stock and may, if appropriate, consider implementing available options, including effecting a reverse stock split. There can be no assurance
that the Company will be able to regain compliance with the Minimum Bid Price Rule or maintain compliance with the other listing requirements
necessary for the Company to maintain the listing of its common stock on The NASDAQ Capital Market.
The
Notice has no effect on the listing of the Company’s shares at this time and the Company’s common stock will continue to
trade on The NASDAQ Capital Market under the symbol “MKD.”
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Molecular Data Inc.
|
|
|
|
|
|
By
|
:
|
/s/ Steven Foo
|
|
Name
|
:
|
Steven Foo
|
|
Title
|
:
|
Chief Executive Officer and Chief Financial Officer
|
Date:
November 30, 2021
Molecular Data (NASDAQ:MKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Molecular Data (NASDAQ:MKD)
Historical Stock Chart
From Jul 2023 to Jul 2024